IN8bio director granted options for 22,000 shares

IN8BIO, INC. director Jeremy R. Graff received a grant of stock options covering 22,000 shares of common stock.

Rhea-AI Filing Summary

IN8BIO, INC. director Jeremy R. Graff received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $1.5800 per share and expire on May 9, 2036. One-twelfth of the options vest monthly starting June 9, 2026, or they become fully vested on the date of the company’s next annual stockholder meeting if he continues providing service.

Insider Trade Summary

Grant/Award: 22,000 shares

Grant/Award 1 txn

Insider Graff Jeremy R.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,000 contracts (Direct)

Footnotes (1)

1. F1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Key Figures

Option grant size: 22,000 shares Exercise price: $1.5800 per share Shares underlying options: 22,000 shares +2 more

5 metrics

Option grant size 22,000 shares Stock options covering common stock granted to director

Exercise price $1.5800 per share Strike price for stock option grant

Shares underlying options 22,000 shares Underlying IN8BIO common stock for the options

Expiration date May 9, 2036 Option term end date

Vesting commencement June 9, 2026 Start of monthly vesting in 12 installments

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "1.5800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"fully vested on the date of the Company's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IN8BIO (INAB) director Jeremy Graff report in this Form 4?

Jeremy R. Graff reported receiving a grant of stock options for 22,000 IN8BIO common shares. These options were awarded as compensation and give him the right to buy shares at a fixed exercise price if vesting and service conditions are met.

How many IN8BIO (INAB) shares are covered by Jeremy Graff’s new options?

The stock option grant covers 22,000 shares of IN8BIO common stock. This represents the number of shares he may purchase upon exercise, subject to vesting and his continued service with the company through the required dates.

What is the exercise price of Jeremy Graff’s IN8BIO (INAB) stock options?

The options have an exercise price of $1.5800 per share. This means Graff can buy IN8BIO common stock at this fixed price for each vested option, regardless of the market price at the time of exercise.

When do Jeremy Graff’s IN8BIO (INAB) options start vesting and when do they fully vest?

One-twelfth of the options vest in equal monthly installments starting on June 9, 2026. However, they will in any case be fully vested on the date of IN8BIO’s next annual stockholder meeting if he continues providing service through that date.

When do Jeremy Graff’s IN8BIO (INAB) stock options expire?

The options expire on May 9, 2036. After this expiration date, any unexercised and vested options will no longer be exercisable, so potential value from the award depends on exercising before that deadline if conditions are satisfied.

Is Jeremy Graff’s Form 4 transaction a market purchase or sale of IN8BIO (INAB) stock?

The Form 4 reflects a grant of stock options, not a market purchase or sale of shares. It records a compensation-related acquisition of derivative securities that may later be exercised into common stock if vesting and service conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Graff Jeremy R.

(Last) (First) (Middle)

C/O IN8BIO

350 5TH AVENUE, SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.58	05/09/2026		A		22,000		(1)	05/09/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)